Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
1. Mounjaro showed heart health benefits compared to Trulicity in recent trials. 2. Mounjaro reduced cardiovascular risks by 8%, with additional comprehensive benefits. 3. Eli Lilly plans to submit heart health data to regulators by year-end 2024. 4. Trulicity's patent expiration in 2027 could enhance Mounjaro's market position. 5. Analysts doubt whether Mounjaro will significantly alter physician prescribing behaviors.